Innovative research on the prevention and control of influenza A H1N1 pandemic won the first prize of National Science and Technology Progress Award

The 2014 National Science and Technology Awards Conference was held in Beijing today. "China's first effective prevention and control and integration innovation research on the 2009 H1N1 influenza pandemic" won the first prize of the National Science and Technology Progress Award. Its 8 major innovations are as follows:

Innovation point 1: Under the leadership of the State Council, a joint prevention and control mechanism led by the Ministry of Health and involving various ministries and commissions was established. Promoting scientific and technological innovation through mechanism innovation and supporting epidemic prevention and control with scientific and technological innovation has enabled China to effectively intervene and control the influenza pandemic for the first time in human history.

Innovation point 2: The first successful development of diagnostic reagents in the world. Obtained a patent for invention. It has been adopted by the World Health Organization to promote the world. It also provided reagents and technologies to 13 developing countries and regions to help them prevent and control influenza A.

Innovation point 3: The hypothesis that the basic propagation coefficient is proved for the first time is correct. There is a theoretical hypothesis: It is believed that in the early stage of the prevalence of the basic propagation coefficient R0<1.8, it is possible to effectively avoid the epidemic peaks in large cities with concentrated populations by medically isolating the source of infection. But it has never been proven, but it has been proved by our strict scientific data. I have to present a unique and popular single peak in China, which is different from the two natural peaks in Europe and the Americas and other countries and regions. It is called the “China Platform”.

Innovation point 4: Accurately reveal the clinical characteristics and influencing factors of A stream, and establish the largest clinical database of A stream in the world, which is recognized by the international community. A major breakthrough has been made in the treatment of severe cases of severe cases in China. The Lee's therapy, which first proposed "four anti-one balance", significantly reduced the mortality rate. Eliminate the panic of the masses on the flow of people and stabilize the people.

Innovation point 5: For the first time, the modern Chinese evidence-based medicine method is used to confirm that traditional Chinese medicine decoction is safe and effective in treating a stream, and it has become a milestone in the prevention and control of infectious diseases in the world.

Innovation point 6: Firstly, a successful influenza A vaccine was developed internationally. The first research strategy to crack a non-adjuvant vaccine was proposed to reduce the endotoxin content and reduce side effects to ensure safety. The results showed that a single injection of 15 μg vaccine without adjuvant had obvious protective effect, and the safety was high. A successful vaccine was developed within 87 days, breaking the world record, and the protection rate can reach 87.3%. The country has inoculated more than 100 million doses (105 million), effectively curbing the spread of the pandemic. Overturned the World Health Organization's recommendation to vaccinate the pandemic vaccine for two doses, providing an important scientific basis for global vaccine production and use.

Innovation point 7: It is proved for the first time that the A-stream vaccine has nothing to do with Guillain-Barre syndrome (GBS), because there may be one case per million people in the general population; the number of cases studied can not explain the problem. We have counted 70 million cases through the Internet, clearly demonstrating that the A-stream vaccine has nothing to do with Guillain-Barre syndrome (GBS), and the incidence of adverse reactions is not higher than the seasonal influenza vaccine, providing a safe basis for global influenza A vaccination. At the same time, this also promoted the adoption of the World Health Organization vaccine regulatory assessment in 2011, which enabled China's vaccine to go abroad for the first time, ending the history of domestic vaccines not being procured by international organizations.

Innovation 8: Innovative basic research addresses the underlying scientific issues of vaccine effectiveness in prevention and control. The crystal structure of the new influenza A virus HA protein was successfully analyzed for the first time. The three-dimensional structure explained the antigenic determinant shared by the influenza A virus with the 1918 influenza virus and the seasonal influenza virus. The molecular structure level clarified that the vaccine only needs one The needle is an effective scientific foundation.

A systematic evaluation was conducted by a third party headed by Professor Xue Wei, Dean of the School of Public Administration of Tsinghua University. The results show that our eight international first research results have significantly reduced our morbidity and mortality, reduced the incidence of 250 million people and hospitalization of 70,000 people, and the mortality rate is five times lower than that of the international community; the social benefit is about 200 billion. Yuan; cost-benefit ratio: 1 yuan VS7.5 ~ 10.84 yuan. China has never declared a state of health emergency like other countries, safeguarding social stability and steady economic growth, and ensuring the smooth progress of large-scale events such as the 60th anniversary of the National Day.

The above research results are published in world-class academic journals. He won 2 first prizes for national scientific and technological progress and 11 new drug certificates. In 2010, China became the first WHO WHO Center for Influenza Reference and Research Cooperation.

The comprehensive technology network system for sudden infectious diseases established through the research of this project played an important role in the H7N9 bird flu epidemic in China and the Ebola virus epidemic in West Africa in 2013.

The above research was undertaken by more than 10 major projects such as major infectious diseases, and 29 units including the China Center for Disease Control and Prevention completed 46 people.